Dr. Laura E. Hogan
Claim this profileStony Brook University Medical Center
Expert in Tumors
Expert in Lymphoma
33 reported clinical trials
82 drugs studied
Area of expertise
1Tumors
Global LeaderStage I
Stage IV
Stage II
2Lymphoma
Global LeaderStage IV
Stage I
Stage II
Affiliated Hospitals
Clinical Trials Laura E. Hogan is currently running
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
Inotuzumab Ozogamicin
for Acute Lymphoblastic Leukemia
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. This trial also studies the outcomes of patients with mixed phenotype acute leukemia (MPAL), and B-lymphoblastic lymphoma (B-LLy) when treated with ALL therapy without inotuzumab ozogamicin. Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers calicheamicin to kill them. Other drugs used in the chemotherapy regimen, such as cyclophosphamide, cytarabine, dexamethasone, doxorubicin, daunorubicin, methotrexate, leucovorin, mercaptopurine, prednisone, thioguanine, vincristine, and pegaspargase or calaspargase pegol work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial will also study the outcomes of patients with mixed phenotype acute leukemia (MPAL) and disseminated B lymphoblastic lymphoma (B-LLy) when treated with high-risk ALL chemotherapy. The overall goal of this study is to understand if adding inotuzumab ozogamicin to standard of care chemotherapy maintains or improves outcomes in High Risk B-cell Acute Lymphoblastic Leukemia (HR B-ALL). The first part of the study includes the first two phases of therapy: Induction and Consolidation. This part will collect information on the leukemia, as well as the effects of the initial treatment, to classify patients into post-consolidation treatment groups. On the second part of this study, patients with HR B-ALL will receive the remainder of the chemotherapy cycles (interim maintenance I, delayed intensification, interim maintenance II, maintenance), with some patients randomized to receive inotuzumab. The patients that receive inotuzumab will not receive part of delayed intensification. Other aims of this study include investigating whether treating both males and females with the same duration of chemotherapy maintains outcomes for males who have previously been treated for an additional year compared to girls, as well as to evaluate the best ways to help patients adhere to oral chemotherapy regimens. Finally, this study will be the first to track the outcomes of subjects with disseminated B-cell Lymphoblastic Leukemia (B-LLy) or Mixed Phenotype Acute Leukemia (MPAL) when treated with B-ALL chemotherapy.
Recruiting2 awards Phase 3
More about Laura E. Hogan
Clinical Trial Related7 years of experience running clinical trials · Led 33 trials as a Principal Investigator · 15 Active Clinical TrialsTreatments Laura E. Hogan has experience with
- Cyclophosphamide
- Vincristine Sulfate
- Radiation Therapy
- Etoposide
- Methotrexate
- Nivolumab
Breakdown of trials Laura E. Hogan has run
Tumors
Lymphoma
Leukemia
Lymphoblastic Leukemia-Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Laura E. Hogan specialize in?
Laura E. Hogan focuses on Tumors and Lymphoma. In particular, much of their work with Tumors has involved Stage I patients, or patients who are Stage IV.
Is Laura E. Hogan currently recruiting for clinical trials?
Yes, Laura E. Hogan is currently recruiting for 11 clinical trials in Stony Brook New York. If you're interested in participating, you should apply.
Are there any treatments that Laura E. Hogan has studied deeply?
Yes, Laura E. Hogan has studied treatments such as Cyclophosphamide, Vincristine Sulfate, Radiation Therapy.
What is the best way to schedule an appointment with Laura E. Hogan?
Apply for one of the trials that Laura E. Hogan is conducting.
What is the office address of Laura E. Hogan?
The office of Laura E. Hogan is located at: Stony Brook University Medical Center, Stony Brook, New York 11794 United States. This is the address for their practice at the Stony Brook University Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.